Several years ago, we reviewed a paper suggesting that estrogen may have beneficial effects for women with schizophrenia. In this study, women with schizophrenia were treated with estrogen in addition to their antipsychotic medications. Adjunctive [...]
This article in Psychiatric Times reviews some interesting research which suggests that drugs which modulate the estrogen receptor may improve cognitive functioning in patients with schizophrenia. This is the first study to show that oral [...]
Several years ago, we reviewed a paper suggesting that estrogen may be a beneficial treatment for women with schizophrenia. In this study, patients with schizophrenia were treated with estrogen. There was significant improvement in their [...]
Aromatase inhibitors (AIs) are the preferred hormonal therapy for postmenopausal women with estrogen sensitive breast cancer. While the selective estrogen receptor modulators (SERMs), such as tamoxifen and raloxifene, are used in premenopausal women with estrogen sensitive breast cancer, the aromatase inhibitors (e.g., anastrozole, letrozole, and exemestane) have been shown to be more effective and safer than the SERMs in postmenopausal women.
